No Data
Laekna Obesity Drug Begins Clinical Study
Laekna Starts Investigational New Drug-Enabling Study for Muscle Weakness Pill
Lai Kai Pharmaceuticals-B (02105.HK) completed the issuance with a total of 17.636 million shares.
On November 27, Glonghui reported that Kai Medical-B (02105.HK) announced that the board of directors is pleased to declare that all conditions for the placement have been met, and the placement was completed on November 27, 2024. According to the terms and conditions of the placement agreement, 17,636,000 shares were successfully placed by the exclusive placing agent at a placement price of 13.36 Hong Kong dollars per share to no fewer than six assignees.
Eli Lilly and Co (LLY.US) cancels double injections, brewing super BD for muscle gain and fat loss.
GLP-1 dual heroes Semaglutide and Tirzepatide, the total sales in 2024 will exceed $40 billion, leading to a huge demand in the muscle-building drug market.
Astrazeneca's Capivasertib for prostate cancer has successfully completed Phase III trials, and the outlook for Kairui Pharmaceutical-B (2105.HK) AKT inhibitors is bullish.
On November 25th, AstraZeneca announced the success of its AKT inhibitor Capivasertib in the phase III CAPItello-281 study for the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Following the approval and launch of Capivasertib for breast cancer indications, this study further confirmed the clinical value of AKT inhibitors. AKT inhibitors, as drugs that have shown potential in multiple cancers such as breast cancer, prostate cancer, and ovarian cancer, have a very broad market outlook. In recent years, an increasing number of pharmaceutical companies have begun to pay attention to AKT inhibitors.
Hong Kong Stock Market News | Lai Kai Pharmaceuticals-B (02105) rose more than 22%, hitting a new high for the year. Recently announced clinical cooperation with eli lilly and co on a new type of weight loss drug.
The stock price of Lai Kai Pharmaceutical-B (02105) rose by over 22%, reaching a high of HK$17.4, setting a new high for the year. As of the time of publication, it has increased by 22.48%, trading at HK$17, with a turnover of 0.178 billion Hong Kong dollars.
No Data
No Data